Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · IEX Real-Time Price · USD
1.840
+0.030 (1.66%)
At close: Jul 2, 2024, 4:00 PM
1.890
+0.050 (2.72%)
After-hours: Jul 2, 2024, 7:44 PM EDT
Company Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc.
Country | United States |
Founded | 2015 |
IPO Date | Oct 20, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 5 |
CEO | Martin A. Lehr |
Contact Details
Address: 2001 Market Street, Suite 3915 Unit #15 Philadelphia, Pennsylvania 19103 United States | |
Phone | 267-225-7416 |
Website | contexttherapeutics.com |
Stock Details
Ticker Symbol | CNTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001842952 |
CUSIP Number | 21077P108 |
ISIN Number | US21077P1084 |
Employer ID | 86-3738787 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Martin A. Lehr | Co-Founder, President, Chief Executive Officer and Director |
Jennifer Minai-Azary | Chief Financial Officer and Treasurer |
Alex C. Levit Esq. | Chief Legal Officer and Corporate Secretary |
Christopher Beck M.B.A. | Senior Vice President of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 14, 2024 | 8-K | Current Report |
Jun 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
May 31, 2024 | EFFECT | Notice of Effectiveness |
May 31, 2024 | 424B3 | Prospectus |
May 29, 2024 | UPLOAD | Filing |
May 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
May 24, 2024 | S-3 | Registration statement under Securities Act of 1933 |
May 16, 2024 | D | Notice of Exempt Offering of Securities |
May 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
May 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |